Anbio Biotechnology is classed by the SEC under In Vitro & In Vivo Diagnostic Substances (industry code 2835), based in Frankfurt Am Main, DE. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $9 million and a profit of $6 million (its filed statements).
Pre-revenue companyIn Vitro & In Vivo Diagnostic SubstancesFrankfurt Am Main, DEfilings since 20238 of 9 filed, 1 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a pre-revenue company: no meaningful revenue on file yet (industry code 2835), so it is read as a pre-revenue company; the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 5.7 out of ten, 8 of 9 metrics filed and 1 estimated: past 4.4 out of ten, present 6.0 out of ten, future 6.3 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 8.9 out of ten. No warning events in its filings since 2023. 89th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 4.6 out of ten. -28.4% a year over 4 filed years; profitable in 4 of 4. 46th percentile among 17 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 1.1 out of ten. Share count grew 7479.5% a year. 0% of cash flow returned. Insiders: 0 sales, 0 purchases. 11th percentile among 5 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Financial health (present): 7.7 out of ten. ROE 21%: 21¢ of profit per shareholder dollar. Leverage 0%: owes 0¢ per asset dollar. 77th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 5.0 out of ten. top 50% of 17 in its family; net margin 74.1%. 50th percentile among 17 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 4.4 out of ten. CrossAssetData estimate 4.4/10, confidence 20 of 100 (family median). 50th percentile among 15 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Room to expand (future): 5.5 out of ten. top 45% of 16 in its family for room to expand. 55th percentile among 16 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 6.2 out of ten. top 38% of 17 in its family for growth drivers. 62nd percentile among 17 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 7.4 out of ten. top 26% of 16 in its family for expectations against reality. 74th percentile among 16 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 20-F filed 2026-04-07 for the period ended 2025-12-31 (on EDGAR). Newest filing: Form F-3ASR, 2026-07-09. Filings on record since 2023. Read from EDGAR 2026-10-12.
Where the revenue comes from
By geography: European Union 60%, Asia Pacific 18%, Other Regions 16%, North America 3%, South America 3%. As tagged in its annual report (Form 20-F, filed 2026-04-07).
Who runs it
Lau, Michael (CEO); Song, Suki (CFO); Tian, Chris (CBO); Hsu, David H (director); Zhang, Michael W.c (director); Hartzler, Nancy (director); Xu, Cany (director). 7 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.